A new review shows how chitosan-based nanovaccines could protect fragile antigens, boost mucosal immunity, and reduce cold-chain dependence, but clinical approval still depends on stronger safety, stability, and manufacturing evidence.
Study: Chitosan nanoparticles for mucosal and needle-free vaccination. Image Credit: Corona Borealis Studio / Shutterstock
Vaccine development is increasingly exploring advanced biomaterials to overcome the logistical and biological limitations of conventional vaccines. A recent review published in the journal npj Vaccines examined how nanotechnology could support more thermostable, potentially cold-chain-independent vaccine delivery systems.
By focusing on chitosan, a natural cationic polymer, the review describes how researchers have developed nanostructures that protect fragile antigens while enhancing both systemic and mucosal immune responses. The findings highlight the key structure-function relationships underlying these platforms and their potential to support scalable, needle-free vaccination strategies.
Addressing Logistical Challenges in Vaccine Storage
Conventional vaccines face challenges, including reliance on refrigerated storage and limited effectiveness at mucosal surfaces, the primary entry points for infectious pathogens. To address these limitations, researchers have explored chitosan, a natural cationic polysaccharide derived from chitin. Its molecular structure resembles that of the mammalian extracellular matrix, providing excellent biocompatibility and controlled biodegradation.
Chitosan is gradually broken down by lysozyme enzymes into non-toxic byproducts, enabling safe interaction with tissues; however, degradation rates vary with formulation, molecular weight, degree of deacetylation, and cross-linking strategy. Its properties can be further tuned by adjusting the degree of deacetylation or through cross-linking strategies, such as treatment with genipin, which improves structural stability and protects sensitive vaccine antigens.
Fabrication and Modification Techniques
Researchers examined the fabrication methods, chemical modifications, and quality control needed to advance chitosan-based nanovaccines. They focused on developing chitosan derivatives with improved solubility, stability, and antigen delivery performance.
Quaternization produces derivatives such as N-trimethyl chitosan (TMC) and N-(2-hydroxypropyl)-3-trimethyl chitosan (HTCC), which carry a permanent positive charge that enhances nucleic acid binding and delivery. Carboxymethylation improves solubility at physiological pH, facilitating the encapsulation of sensitive proteins and viral antigens. Acylation and alkylation generate amphiphilic derivatives that strengthen interactions with biological membranes and improve cellular uptake.
The study also discussed several fabrication techniques. Ionic gelation using tripolyphosphate is used because it operates under mild conditions that preserve antigen integrity. Nanoprecipitation can produce highly uniform nanoparticles with diameters ranging from 20 to 100 nanometers, suitable for intracellular delivery. Spray drying enabled the conversion of liquid into stable dry powders for storage and inhalable vaccine applications.
To ensure consistent performance, these nanomaterials undergo extensive characterization. DLS measures particle size and polydispersity, while zeta potential analysis assesses colloidal stability, aiming for values greater than ±30 mV. Structural features such as particle morphology and core-shell architecture are examined using TEM, SEM, and AFM.
Mechanisms Enhancing Immune Response Activation
The review highlighted mechanisms through which chitosan-based nanostructures may enhance immune responses after uptake by antigen-presenting cells (APCs), including macrophages and dendritic cells. Following endocytosis, the amino groups of chitosan become increasingly protonated within the acidic endosomal environment. This may promote endosomal swelling and membrane destabilization, thereby facilitating the release of encapsulated antigens into the cytosol. The released antigens are then proteasomally processed and presented via the MHC I pathway.
Endosomal disruption also may serve as a key immunostimulatory signal in selected chitosan-based formulations, activating the NLRP3 inflammasome and leading to the maturation and release of pro-inflammatory cytokines, including IL-1β and IL-18, thereby amplifying immune responses. The study also described activation of the cGAS-STING pathway, in which cellular stress and mitochondrial DNA release stimulate cGAS, triggering downstream STING signaling and the production of type I interferons, which are crucial for antiviral immunity.
Enhancing Mucosal Delivery and Targeted Administration
Chitosan-based nano-adjuvants are considered promising for mucosal vaccine delivery due to their strong mucoadhesive properties. In intranasal and pulmonary applications, positively charged nanoparticles interact with negatively charged sialic acid residues on epithelial surfaces. This prolongs residence time by reducing mucociliary clearance and can temporarily open epithelial tight junctions, enhancing antigen transport to lymphoid tissues.
For oral vaccination, chitosan nanoparticles are often incorporated into protective composite systems, such as alginate-coated formulations. These coatings shield vaccine antigens from acidic gastric conditions and enzymatic degradation during gastrointestinal transit. Once the particles successfully reach the small intestine, the protective layer dissolves, releasing the antigen payload and improving uptake by gut-associated lymphoid tissues.
Future Directions for Scalable Vaccine Platforms
In summary, preclinical studies indicate that chitosan-based nanovaccine systems can substantially improve vaccine stability and delivery. In one accelerated-stability example, spray-dried influenza vaccine powders using chitosan carriers preserved antigen integrity for up to three months at temperatures as high as 60°C, highlighting their potential to reduce or eliminate dependence on cold-chain storage during distribution. However, long-term real-time stability data under regulatory conditions remain limited.
Despite these results, clinical translation remains at an early stage. Initial Phase I and II studies of intranasal chitosan-based influenza vaccines have shown favorable safety profiles and local mucosal IgA responses. However, immune responses in humans have been less consistent than those observed in animal models, underscoring the challenges of translating preclinical findings into clinical efficacy. No chitosan nanoparticle-based vaccine has yet received clinical approval. Further progress will depend on developing standardized, pharmaceutical-grade chitosan materials with well-defined molecular weights and degrees of deacetylation to ensure reproducible production under Good Manufacturing Practice.
Future work should clarify long-term safety, epithelial barrier recovery following transient opening of tight junctions, and the molecular interactions between antigens and polymer matrices. Overall, addressing these challenges will be key for advancing needle-free, self-administrable vaccines for routine immunization and future pandemic preparedness.
